Roivant, which creates companies around orphaned drugs, just raised $1.1 billion from Softbank
August 09, 2017 at 08:32 AM EDT
Roivant Sciences, a three-year-old, New York-based company aiming to one day be a giant holding company for dozens of independent biopharmaceutical companies, has raised $1.1 billion in equity led by the Softbank Vision Fund — making it the latest in a string of enormous bets by Softbank, and putting the young outfit more squarely on the radar of the tech world. Roivant focuses on… Read More
